To receive the Femtech World newsletter, sign up here.
News
Start-up announces partnership to address maternal health disparities
A new partnership seeks to better understand Black maternal health disparities in the US
The US digital health start-up Acclinate has partnered with the tech company Quilt.AI to interpret internet data and “intensify” its Black maternal health initiatives.
Black women in the United States are facing a maternal mortality rate three times higher than that of white women.
Acclinate, a start-up which specialises in predictive analytics technology and community engagement, focuses on accessing and engaging communities of colour, aiming to empower informed health decisions and promote clinical trial participation.
Over the past year, the company’s NOWINCLUDED community platform has engaged directly with Black mothers, gathering insights through the Mommy Listening Tour, a campaign focused on better understanding the health perspectives of Black mums.
The tour, which utilised digital and in-person efforts, revealed that 75 per cent of Black mothers trust OB/GYNs for reliable health information, and over 51 per cent are willing to travel up to 10 miles for quality maternal care.
The start-up is now using additional findings from Quilt.AI’s platform, which has been analysing online conversations about Black maternal health, for a comprehensive report.
“Leveraging these insights allows us to tailor our initiatives more effectively, ensuring we address the nuanced challenges Black mothers face in healthcare,” said Tiffany Whitlow, co-founder and chief development officer at Acclinate.
“Our Mommy Listening Tour and most recent listening experiences at the Black Maternal Health Expo have been invaluable, offering direct feedback from our community so we can work together to advocate for better maternal health outcomes.”
Whitlow said the report had confirmed a significant 75 per cent of online discussions highlight a pressing need for better support systems for Black mothers, while another 63 per cent underscore a demand for more culturally competent healthcare providers.
Additional insights indicated a substantial conversation around the need for mental health support, with many Black mothers expressing a lack of accessible resources to manage postpartum depression.
Anurag Banerjee, co-founder and chief executive officer of Quilt.AI, said: “We’re extremely excited to partner with Acclinate and contribute our AI tools to uncover meaningful health insight to support Acclinate’s mission and help drive positive impact and better serve Black women in the community.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Hormonal health2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






